Elevated risk of type 2 diabetes for development of Alzheimer disease: A key role for oxidative stress in brain

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 9, 2014, Pages 1693-1706

  Butterfield, D Allan ^a,b   Di Domenico, Fabio ^c   Barone, Eugenio ^c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Alzheimer disease; Heme oxygenase 1 and biliverdin reductase; Insulin; Oxidative stress; Protein oxidation; Type 2 diabetes mellitus and insulin resistance

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEME OXYGENASE 1; HEME OXYGENASE 2; INSULIN; METFORMIN; PROTEIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SULFONYLUREA DERIVATIVE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; AMYLOID BETA PROTEIN; ATORVASTATIN; EXENDIN 4; GENIPOSIDE; GLIBENCLAMIDE; GLICLAZIDE; HEME OXYGENASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LETEPRINIM; LIRAGLUTIDE; LIXISENATIDE; METFORMIN PLUS SITAGLIPTIN; NONSTEROID ANTIINFLAMMATORY AGENT; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SOMATOMEDIN C; TAU PROTEIN; TROGLITAZONE; UNINDEXED DRUG; VILDAGLIPTIN;

ALZHEIMER DISEASE; BRAIN; DIABETOGENESIS; DISEASE ASSOCIATION; DISEASE COURSE; GLUCOSE METABOLISM; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN TREATMENT; LIPID PEROXIDATION; MOLECULAR PATHOLOGY; NEUROPATHOLOGY; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW; RISK ASSESSMENT; AMNESIA; ANTIOXIDANT ACTIVITY; BRAIN CELL; CELL ACTIVATION; CELL RESPIRATION; COGNITIVE DEFECT; DRUG EFFICACY; DRUG MECHANISM; EXCITOTOXICITY; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HEPATITIS; HYPOGLYCEMIA; INSULIN SYNTHESIS; LEARNING DISORDER; LIVER INJURY; LOW DRUG DOSE; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; MOLECULAR INTERACTION; NERVE CELL PLASTICITY; NEUROFIBRILLARY TANGLE; PATHOGENESIS; PROTEIN PHOSPHORYLATION; RISK FACTOR; SENILE PLAQUE; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; HEME OXYGENASE 1 AND BILIVERDIN REDUCTASE; INSULIN; OXIDATIVE STRESS; PROTEIN OXIDATION; TYPE-2 DIABETES MELLITUS AND INSULIN RESISTANCE;

ALZHEIMER DISEASE; BRAIN; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HUMANS; OXIDATIVE STRESS; RISK FACTORS;

EID: 84904113244     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.06.010     Document Type: Review

References (224)

1. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N. Engl. J. Med. 2010, 362:329-344.
2. Mayeux R. Clinical practice. Early Alzheimer's disease. N. Engl. J. Med. 2010, 362:2194-2201.
3. Akter K., Lanza E.A., Martin S.A., Myronyuk N., Rua M., Raffa R.B. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?. Br. J. Clin. Pharmacol. 2011, 71:365-376.
4. Ott A., Stolk R.P., Hofman A., van Harskamp F., Grobbee D.E., Breteler M.M. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 1996, 39:1392-1397.
5. Luchsinger J.A., Tang M.X., Shea S., Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004, 63:1187-1192.
6. Ronnemaa E., Zethelius B., Sundelof J., Sundstrom J., Degerman-Gunnarsson M., Berne C., Lannfelt L., Kilander L. Impaired insulin secretion increases the risk of Alzheimer disease. Neurology 2008, 71:1065-1071.
7. Morris J.K., Vidoni E.D., Honea R.A., Burns J.M., I.Alzheimer's Disease Neuroimaging Impaired glycemia increases disease progression in mild cognitive impairment. Neurobiol. Aging 2014, 35:585-589.
8. Pluta R. Blood-brain barrier dysfunction and amyloid precursor protein accumulation in microvascular compartment following ischemia-reperfusion brain injury with 1-year survival. Acta Neurochir. Suppl. 2003, 86:117-122.
9. Sadowski M., Pankiewicz J., Scholtzova H., Li Y.S., Quartermain D., Duff K., Wisniewski T. Links between the pathology of Alzheimer's disease and vascular dementia. Neurochem. Res. 2004, 29:1257-1266.
10. de la Monte S.M., Wands J.R. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J. Alzheimers Dis. 2005, 7:45-61.
11. Janson J., Laedtke T., Parisi J.E., O'Brien P., Petersen R.C., Butler P.C. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004, 53:474-481.
12. Freude S., Schilbach K., Schubert M. The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: from model organisms to human disease. Curr. Alzheimer Res. 2009, 6:213-223.
13. Plum L., Schubert M., Bruning J.C. The role of insulin receptor signaling in the brain. Trends Endocrinol. Metab. 2005, 16:59-65.
14. Horwood J.M., Dufour F., Laroche S., Davis S. Signalling mechanisms mediated by the phosphoinositide 3-kinase/Akt cascade in synaptic plasticity and memory in the rat. Eur. J. Neurosci. 2006, 23:3375-3384.
15. Chiang H.C., Wang L., Xie Z., Yau A., Zhong Y. PI3 kinase signaling is involved in Abeta-induced memory loss in Drosophila. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:7060-7065.
16. Calabrese V., Mancuso C., Calvani M., Rizzarelli E., Butterfield D.A., Stella A.M. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat. Rev. Neurosci. 2007, 8:766-775.
17. Lebovitz H.E. Insulin resistance: definition and consequences. Exp. Clin. Endocrinol. Diabetes 2001, 109(Suppl. 2):S135-S148.
18. Cholerton B., Baker L.D., Craft S. Insulin, cognition, and dementia. Eur. J. Pharmacol. 2013, 719:170-179.
19. Banks W.A., Jaspan J.B., Kastin A.J. Selective, physiological transport of insulin across the blood-brain barrier: novel demonstration by species-specific radioimmunoassays. Peptides 1997, 18:1257-1262.
20. Baskin D.G., Figlewicz D.P., Woods S.C., Porte D., Dorsa D.M. Insulin in the brain. Annu. Rev. Physiol. 1987, 49:335-347.
21. Hill J.M., Lesniak M.A., Pert C.B., Roth J. Autoradiographic localization of insulin receptors in rat brain: prominence in olfactory and limbic areas. Neuroscience 1986, 17:1127-1138.
22. Havrankova J., Roth J., Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature 1978, 272:827-829.
23. Baskin D.G., Wilcox B.J., Figlewicz D.P., Dorsa D.M. Insulin and insulin-like growth factors in the CNS. Trends Neurosci. 1988, 11:107-111.
24. Havrankova J., Schmechel D., Roth J., Brownstein M. Identification of insulin in rat brain. Proc. Natl. Acad. Sci. U. S. A. 1978, 75:5737-5741.
25. Ghasemi R., Haeri A., Dargahi L., Mohamed Z., Ahmadiani A. Insulin in the brain: sources, localization and functions. Mol. Neurobiol. 2013, 47:145-171.
26. Freiherr J., Hallschmid M., Frey W.H., Brunner Y.F., Chapman C.D., Holscher C., Craft S., De Felice F.G., Benedict C. Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs 2013, 27:505-514.
27. Ghasemi R., Dargahi L., Haeri A., Moosavi M., Mohamed Z., Ahmadiani A. Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders. Mol. Neurobiol. 2013, 47:1045-1065.
28. Rivera E.J., Goldin A., Fulmer N., Tavares R., Wands J.R., de la Monte S.M. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J. Alzheimers Dis. 2005, 8:247-268.
29. Steen E., Terry B.M., Rivera E.J., Cannon J.L., Neely T.R., Tavares R., Xu X.J., Wands J.R., de la Monte S.M. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes?. J. Alzheimers Dis. 2005, 7:63-80.
30. Talbot K., Wang H.Y., Kazi H., Han L.Y., Bakshi K.P., Stucky A., Fuino R.L., Kawaguchi K.R., Samoyedny A.J., Wilson R.S., Arvanitakis Z., Schneider J.A., Wolf B.A., Bennett D.A., Trojanowski J.Q., Arnold S.E. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 2012, 122:1316-1338.
31. Hoyer S. Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis. J. Neural Transm. 1998, 105:415-422.
32. de la Monte S.M. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs 2012, 72:49-66.
33. Talbot K., Wang H.Y. The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease. Alzheimers Dement. 2014, 10:S12-S25.
34. Watson G.S., Craft S. Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. Eur. J. Pharmacol. 2004, 490:97-113.
35. Schwartz M.W., Figlewicz D.F., Kahn S.E., Baskin D.G., Greenwood M.R., Porte D. Insulin binding to brain capillaries is reduced in genetically obese, hyperinsulinemic Zucker rats. Peptides 1990, 11:467-472.
36. Wallum B.J., Taborsky G.J., Porte D., Figlewicz D.P., Jacobson L., Beard J.C., Ward W.K., Dorsa D. Cerebrospinal fluid insulin levels increase during intravenous insulin infusions in man. J. Clin. Endocrinol. Metab. 1987, 64:190-194.
37. de la Monte S.M. Relationships between diabetes and cognitive Impairment. Endocrinol. Metab. Clin. N. Am. 2014, 43:245-267.
38. Moreira P.I. Alzheimer's disease and diabetes: an integrative view of the role of mitochondria, oxidative stress, and insulin. J. Alzheimers Dis. 2012, 30(Suppl. 2):S199-S215.
39. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007, 39:44-84.
40. Droge W. Free radicals in the physiological control of cell function. Physiol. Rev. 2002, 82:47-95.
41. De Felice F.G. Alzheimer's disease and insulin resistance: translating basic science into clinical applications. J. Clin. Invest. 2013, 123:531-539.
42. Butterfield D.A. Oxidative stress in neurodegenerative disorders. Antioxid. Redox Signal. 2006, 8:1971-1973.
43. Di Domenico F., Perluigi M., Butterfield D.A., Cornelius C., Calabrese V. Oxidative damage in rat brain during aging: interplay between energy and metabolic key target proteins. Neurochem. Res. 2010, 35:2184-2192.
44. Butterfield D.A., Drake J., Pocernich C., Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 2001, 7:548-554.
45. Dominguez R.O., Marschoff E.R., Gonzalez S.E., Repetto M.G., Serra J.A. Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients. Diabetes Res. Clin. Pract. 2012, 98:68-74.
46. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 1997, 23:134-147.
47. Butterfield D.A., Sultana R. Redox proteomics: understanding oxidative stress in the progression of age-related neurodegenerative disorders. Expert Rev. Proteomics 2008, 5:157-160.
48. Butterfield D.A., Perluigi M., Sultana R. Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur. J. Pharmacol. 2006, 545:39-50.
49. Butterfield D.A., Lauderback C.M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic. Biol. Med. 2002, 32:1050-1060.
50. Butterfield D.A., Liqing G., Di Domenico F., Robinson R.A.S. Mass spectrometry and redox proteomics: application in disease. Mass Spectrom. Rev. 2014, 33:277-301.
51. de la Monte S.M. Insulin resistance and Alzheimer's disease. BMB Rep. 2009, 42:475-481.
52. Zhao W.Q., Townsend M. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim. Biophys. Acta 2009, 1792:482-496.
53. Craft S. Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol. Aging 2005, 26(Suppl. 1):65-69.
54. Reddy V.P., Zhu X., Perry G., Smith M.A. Oxidative stress in diabetes and Alzheimer's disease. J. Alzheimers Dis. 2009, 16:763-774.
55. Gerbitz K.D., Gempel K., Brdiczka D. Mitochondria and diabetes, genetic, biochemical, and clinical implications of the cellular energy circuit. Diabetes 1996, 45:113-126.
56. Moreira P.I., Santos M.S., Selca R., Oliveira C.R. Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes. J. Neurol. Sci. 2007, 257:206-214.
57. Neumann K.F., Rojo L., Navarrete L.P., Farias G., Reyes P., Maccioni R.B. Insulin resistance and Alzheimer's disease: molecular links & clinical implications. Curr. Alzheimer Res. 2008, 5:438-447.
58. Maiese K., Chong Z.Z., Shang Y.C. Mechanistic insights into diabetes mellitus and oxidative stress. Curr. Med. Chem. 2007, 14:1729-1738.
59. Cohen E., Bieschke J., Perciavalle R.M., Kelly J.W., Dillin A. Opposing activities protect against age-onset proteotoxicity. Science 2006, 313:1604-1610.
60. de la Monte S.M., Tong M. Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem. Pharmacol. 2014, 88:548-559.
61. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615-1625.
62. Orth M., Schapira A.H. Mitochondria and degenerative disorders. Am. J. Med. Genet. 2001, 106:27-36.
63. Correia S.C., Santos R.X., Santos M.S., Casadesus G., Lamanna J.C., Perry G., Smith M.A., Moreira P.I. Mitochondrial abnormalities in a streptozotocin-induced rat model of sporadic Alzheimer's disease. Curr. Alzheimer Res. 2013, 10:406-419.
64. Santos R.X., Correia S.C., Alves M.G., Oliveira P.F., Cardoso S., Carvalho C., Duarte A.I., Santos M.S., Moreira P.I. Insulin therapy modulates mitochondrial dynamics and biogenesis, autophagy and tau protein phosphorylation in the brain of type 1 diabetic rats. Biochim. Biophys. Acta 2014, 1842:1154-1166.
65. Carvalho C., Cardoso S., Correia S.C., Santos R.X., Santos M.S., Baldeiras I., Oliveira C.R., Moreira P.I. Metabolic alterations induced by sucrose intake and Alzheimer's disease promote similar brain mitochondrial abnormalities. Diabetes 2012, 61:1234-1242.
66. Carvalho C., Machado N., Mota P.C., Correia S.C., Cardoso S., Santos R.X., Santos M.S., Oliveira C.R., Moreira P.I. Type 2 diabetic and Alzheimer's disease mice present similar behavioral, cognitive, and vascular anomalies. J. Alzheimers Dis. 2013, 35:623-635.
67. James D., Kang S., Park S. Injection of beta-amyloid into the hippocampus induces metabolic disturbances and involuntary weight loss which may be early indicators of Alzheimer's disease. Aging Clin. Exp. Res. 2014, 26:93-98.
68. Carvalho C., Katz P.S., Dutta S., Katakam P.V., Moreira P.I., Busija D.W. Increased susceptibility to amyloid-beta toxicity in rat brain microvascular endothelial cells under hyperglycemic conditions. J. Alzheimers Dis. 2014, 38:75-83.
69. Lesort M., Johnson G.V. Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons. Neuroscience 2000, 99:305-316.
70. Lesort M., Jope R.S., Johnson G.V. Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase. J. Neurochem. 1999, 72:576-584.
71. Schechter R., Beju D., Miller K.E. The effect of insulin deficiency on tau and neurofilament in the insulin knockout mouse. Biochem. Biophys. Res. Commun. 2005, 334:979-986.
72. Schubert M., Brazil D.P., Burks D.J., Kushner J.A., Ye J., Flint C.L., Farhang-Fallah J., Dikkes P., Warot X.M., Rio C., Corfas G., White M.F. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J. Neurosci. 2003, 23:7084-7092.
73. Wang J.Z., Wu Q., Smith A., Grundke-Iqbal I., Iqbal K. Tau is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase. FEBS Lett. 1998, 436:28-34.
74. El Khoury N.B., Gratuze M., Papon M.A., Bretteville A., Planel E. Insulin dysfunction and tau pathology. Front. Cell. Neurosci. 2014, 8:22.
75. Takalo M., Haapasalo A., Martiskainen H., Kurkinen K.M., Koivisto H., Miettinen P., Khandelwal V.K., Kemppainen S., Kaminska D., Makinen P., Leinonen V., Pihlajamaki J., Soininen H., Laakso M., Tanila H., Hiltunen M. High-fat diet increases tau expression in the brain of T2DM and AD mice independently of peripheral metabolic status. J. Nutr. Biochem. 2014, 25:634-641.
76. de la Monte S.M. Triangulated mal-signaling in Alzheimer's disease: roles of neurotoxic ceramides, ER stress, and insulin resistance reviewed. J. Alzheimers Dis. 2012, 30(Suppl. 2):S231-S249.
77. Han W., Li C. Linking type 2 diabetes and Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:6557-6558.
78. Gasparini L., Gouras G.K., Wang R., Gross R.S., Beal M.F., Greengard P., Xu H. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J. Neurosci. 2001, 21:2561-2570.
79. Duarte A.I., Santos M.S., Oliveira C.R., Rego A.C. Insulin neuroprotection against oxidative stress in cortical neurons - involvement of uric acid and glutathione antioxidant defenses. Free Radic. Biol. Med. 2005, 39:876-889.
80. Hong F., Kwon S.J., Jhun B.S., Kim S.S., Ha J., Kim S.J., Sohn N.W., Kang C., Kang I. Insulin-like growth factor-1 protects H9c2 cardiac myoblasts from oxidative stress-induced apoptosis via phosphatidylinositol 3-kinase and extracellular signal-regulated kinase pathways. Life Sci. 2001, 68:1095-1105.
81. Rensink A.A., Otte-Holler I., de Boer R., Bosch R.R., ten Donkelaar H.J., de Waal R.M., Verbeek M.M., Kremer B. Insulin inhibits amyloid beta-induced cell death in cultured human brain pericytes. Neurobiol. Aging 2004, 25:93-103.
82. Moloney A.M., Griffin R.J., Timmons S., O'Connor R., Ravid R., O'Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 2010, 31:224-243.
83. O'Neill C. PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer's disease. Exp. Gerontol. 2013, 48:647-653.
84. Perluigi M., Pupo G., Tramutola A., Cini C., Coccia R., Barone E., Head E., Butterfield D.A., Di Domenico F. Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain. Biochim. Biophys. Acta 2014, 1842:1144-1153.
85. 2+ release inducing mitochondrial fragmentation in hippocampal neurons and prevent RyR-mediated dendritic spine remodeling produced by BDNF. Antioxid. Redox Signal. 2011, 14:1209-1223.
86. De Felice F.G., Velasco P.T., Lambert M.P., Viola K., Fernandez S.J., Ferreira S.T., Klein W.L. A beta oligomers induce neuronal oxidative stress through an N-methyl-d-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem. 2007, 282:11590-11601.
87. Zhao W.Q., De Felice F.G., Fernandez S., Chen H., Lambert M.P., Quon M.J., Krafft G.A., Klein W.L. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J. 2008, 22:246-260.
88. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu. Rev. Med. 1995, 46:223-234.
89. Smith M.A., Monnier V.M., Sayre L.M., Perry G. Amyloidosis, advanced glycation end products and Alzheimer disease. Neuroreport 1995, 6:1595-1596.
90. Vitek M.P., Bhattacharya K., Glendening J.M., Stopa E., Vlassara H., Bucala R., Manogue K., Cerami A. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:4766-4770.
91. Ko L.W., Ko E.C., Nacharaju P., Liu W.K., Chang E., Kenessey A., Yen S.H. An immunochemical study on tau glycation in paired helical filaments. Brain Res. 1999, 830:301-313.
92. Li J.J., Surini M., Catsicas S., Kawashima E., Bouras C. Age-dependent accumulation of advanced glycosylation end products in human neurons. Neurobiol. Aging 1995, 16:69-76.
93. Chaney M.O., Stine W.B., Kokjohn T.A., Kuo Y.M., Esh C., Rahman A., Luehrs D.C., Schmidt A.M., Stern D., Yan S.D., Roher A.E. RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling. Biochim. Biophys. Acta 2005, 1741:199-205.
94. Lue L.F., Walker D.G., Brachova L., Beach T.G., Rogers J., Schmidt A.M., Stern D.M., Yan S.D. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp. Neurol. 2001, 171:29-45.
95. Hildreth K.L., Van Pelt R.E., Schwartz R.S. Obesity, insulin resistance, and Alzheimer's disease. Obesity 2012, 20:1549-1557.
96. Blass J.P., Gibson G.E., Hoyer S. The role of the metabolic lesion in Alzheimer's disease. J. Alzheimers Dis. 2002, 4:225-232.
97. Aluise C.D., Robinson R.A., Cai J., Pierce W.M., Markesbery W.R., Butterfield D.A. Redox proteomics analysis of brains from subjects with amnestic mild cognitive impairment compared to brains from subjects with preclinical Alzheimer's disease: insights into memory loss in MCI. J. Alzheimers Dis. 2011, 23:257-269.
98. Butterfield D.A., Sultana R. Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. J. Alzheimers Dis. 2007, 12:61-72.
99. Butterfield D.A., Gnjec A., Poon H.F., Castegna A., Pierce W.M., Klein J.B., Martins R.N. Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: an initial assessment. J. Alzheimers Dis. 2006, 10:391-397.
100. Sultana R., Poon H.F., Cai J., Pierce W.M., Merchant M., Klein J.B., Markesbery W.R., Butterfield D.A. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol. Dis. 2006, 22:76-87.
101. Sultana R., Boyd-Kimball D., Poon H.F., Cai J., Pierce W.M., Klein J.B., Merchant M., Markesbery W.R., Butterfield D.A. Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol. Aging 2006, 27:1564-1576.
102. Butterfield D.A., Perluigi M., Reed T., Muharib T., Hughes C.P., Robinson R.A., Sultana R. Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications. Antioxid. Redox Signal. 2012, 17:1610-1655.
103. Chen Z., Zhong C. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog. Neurobiol. 2013, 108:21-43.
104. Butterfield D.A., Dalle-Donne I. Redox proteomics: from protein modifications to cellular dysfunction and disease. Mass Spectrom. Rev. 2014, 33:1-6.
105. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., Jones P.K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C.S., Petersen R.B., Smith M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2001, 60:759-767.
106. Serra J.A., Marschoff E.R., Dominguez R.O., Guareschi E.M., Famulari A.L., Pagano M.A., de Lustig E.S., A.Collaborative Group for the Study of the Oxidative Stress Oxidative stress in Alzheimer's and vascular dementias: masking of the antioxidant profiles by a concomitant Type II diabetes mellitus condition. J. Neurol. Sci. 2004, 218:17-24.
107. Pandey K.B., Mishra N., Rizvi S.I. Protein oxidation biomarkers in plasma of type 2 diabetic patients. Clin. Biochem. 2010, 43:508-511.
108. Gradinaru D., Borsa C., Ionescu C., Margina D. Advanced oxidative and glycoxidative protein damage markers in the elderly with type 2 diabetes. J. Proteome 2013, 92:313-322.
109. Pan H.Z., Zhang L., Guo M.Y., Sui H., Li H., Wu W.H., Qu N.Q., Liang M.H., Chang D. The oxidative stress status in diabetes mellitus and diabetic nephropathy. Acta Diabetol. 2010, 47(Suppl. 1):71-76.
110. D'Archivio M., Annuzzi G., Vari R., Filesi C., Giacco R., Scazzocchio B., Santangelo C., Giovannini C., Rivellese A.A., Masella R. Predominant role of obesity/insulin resistance in oxidative stress development. Eur. J. Clin. Investig. 2012, 42:70-78.
111. Calabrese V., Cornelius C., Leso V., Trovato-Salinaro A., Ventimiglia B., Cavallaro M., Scuto M., Rizza S., Zanoli L., Neri S., Castellino P. Oxidative stress, glutathione status, sirtuin and cellular stress response in type 2 diabetes. Biochim. Biophys. Acta 2012, 1822:729-736.
112. Di Domenico F., Pupo G., Tramutola A., Giorgi A., Eugenia Schinina M., Coccia R., Head E., Allan Butterfield D., Perluigi M. Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease. Free Radic. Biol. Med. 2014, 71:270-280.
113. Di Domenico F., Coccia R., Cocciolo A., Murphy M.P., Cenini G., Head E., Butterfield D.A., Giorgi A., Schinina M.E., Mancuso C., Cini C., Perluigi M. Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain. Biochim. Biophys. Acta 2013, 1832:1249-1259.
114. Poon H.F., Calabrese V., Scapagnini G., Butterfield D.A. Free radicals: key to brain aging and heme oxygenase as a cellular response to oxidative stress. J. Gerontol. A Biol. Sci. Med. Sci. 2004, 59:478-493.
115. Maines M.D. The heme oxygenase system: a regulator of second messenger gases. Annu. Rev. Pharmacol. Toxicol. 1997, 37:517-554.
116. Maines M.D. The heme oxygenase system and its functions in the brain. Cell. Mol. Biol. (Noisy-le-grand) 2000, 46:573-585.
117. Mancuso C., Barone E. The heme oxygenase/biliverdin reductase pathway in drug research and development. Curr. Drug Metab. 2009, 10:579-594.
118. Butterfield D.A., Barone E., Di Domenico F., Cenini G., Sultana R., Murphy M.P., Mancuso C., Head E. Atorvastatin treatment in a dog preclinical model of Alzheimer's disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain. Int. J. Neuropsychopharmacol. 2012, 15:981-987.
119. Barone E., Di Domenico F., Sultana R., Coccia R., Mancuso C., Perluigi M., Butterfield D.A. Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment. Free Radic. Biol. Med. 2012, 52:2292-2301.
120. Salinas M., Wang J., Rosa de Sagarra M., Martin D., Rojo A.I., Martin-Perez J., Ortiz de Montellano P.R., Cuadrado A. Protein kinase Akt/PKB phosphorylates heme oxygenase-1 in vitro and in vivo. FEBS Lett. 2004, 578:90-94.
121. Sultana R., Perluigi M., Butterfield D.A. Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol. 2009, 118:131-150.
122. Subramaniam R., Roediger F., Jordan B., Mattson M.P., Keller J.N., Waeg G., Butterfield D.A. The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins. J. Neurochem. 1997, 69:1161-1169.
123. Owen J.B., Sultana R., Aluise C.D., Erickson M.A., Price T.O., Bu G., Banks W.A., Butterfield D.A. Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: implications for Abeta accumulation in AD brain. Free Radic. Biol. Med. 2010, 49:1798-1803.
124. Lauderback C.M., Hackett J.M., Huang F.F., Keller J.N., Szweda L.I., Markesbery W.R., Butterfield D.A. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. J. Neurochem. 2001, 78:413-416.
125. Barone E., Di Domenico F., Mancuso C., Butterfield D.A. The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it's time for reconciliation. Neurobiol. Dis. 2014, 62:144-159.
126. Marrazzo G., Bosco P., La Delia F., Scapagnini G., Di Giacomo C., Malaguarnera M., Galvano F., Nicolosi A., Li Volti G. Neuroprotective effect of silibinin in diabetic mice. Neurosci. Lett. 2011, 504:252-256.
127. Nakatsuka I., Maeda S., Andoh T., Hayashi Y., Mizuno R., Higuchi H., Miyawaki T. Oxidative changes in the rat brain by intraperitoneal injection of ferric nitrilotriacetate. Redox Rep. 2009, 14:109-114.
128. Lappalainen J., Lappalainen Z., Oksala N.K., Laaksonen D.E., Khanna S., Sen C.K., Atalay M. Alpha-lipoic acid does not alter stress protein response to acute exercise in diabetic brain. Cell Biochem. Funct. 2010, 28:644-650.
129. Rajpathak S.N., Crandall J.P., Wylie-Rosett J., Kabat G.C., Rohan T.E., Hu F.B. The role of iron in type 2 diabetes in humans. Biochim. Biophys. Acta 2009, 1790:671-681.
130. Swaminathan S., Fonseca V.A., Alam M.G., Shah S.V. The role of iron in diabetes and its complications. Diabetes Care 2007, 30:1926-1933.
131. Smith M.A., Harris P.L., Sayre L.M., Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:9866-9868.
132. Song W., Su H., Song S., Paudel H.K., Schipper H.M. Over-expression of heme oxygenase-1 promotes oxidative mitochondrial damage in rat astroglia. J. Cell. Physiol. 2006, 206:655-663.
133. Schipper H.M., Bennett D.A., Liberman A., Bienias J.L., Schneider J.A., Kelly J., Arvanitakis Z. Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment. Neurobiol. Aging 2006, 27:252-261.
134. Borel M.J., Beard J.L., Farrell P.A. Hepatic glucose production and insulin sensitivity and responsiveness in iron-deficient anemic rats. Am. J. Physiol. 1993, 264:E380-E390.
135. Farrell P.A., Beard J.L., Druckenmiller M. Increased insulin sensitivity in iron-deficient rats. J. Nutr. 1988, 118:1104-1109.
136. Dandona P., Hussain M.A., Varghese Z., Politis D., Flynn D.M., Hoffbrand A.V. Insulin resistance and iron overload. Ann. Clin. Biochem. 1983, 20(Pt 2):77-79.
137. Ferreira S.T., Clarke J.R., Bomfim T.R., De Felice F.G. Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease. Alzheimers Dement. 2014, 10:S76-S83.
138. Mosen H., Salehi A., Henningsson R., Lundquist I. Nitric oxide inhibits, and carbon monoxide activates, islet acid alpha-glucoside hydrolase activities in parallel with glucose-stimulated insulin secretion. J. Endocrinol. 2006, 190:681-693.
139. Henningsson R., Alm P., Ekstrom P., Lundquist I. Heme oxygenase and carbon monoxide: regulatory roles in islet hormone release: a biochemical, immunohistochemical, and confocal microscopic study. Diabetes 1999, 48:66-76.
140. Mosen H., Salehi A., Alm P., Henningsson R., Jimenez-Feltstrom J., Ostenson C.G., Efendic S., Lundquist I. Defective glucose-stimulated insulin release in the diabetic Goto-Kakizaki (GK) rat coincides with reduced activity of the islet carbon monoxide signaling pathway. Endocrinology 2005, 146:1553-1558.
141. Schipper H.M., Gupta A., Szarek W.A. Suppression of glial HO-1 activity as a potential neurotherapeutic intervention in AD. Curr. Alzheimer Res. 2009, 6:424-430.
142. Crichton R.R., Dexter D.T., Ward R.J. Brain iron metabolism and its perturbation in neurological diseases. J. Neural Transm. 2011, 118:301-314.
143. Craft S., Baker L.D., Montine T.J., Minoshima S., Watson G.S., Claxton A., Arbuckle M., Callaghan M., Tsai E., Plymate S.R., Green P.S., Leverenz J., Cross D., Gerton B. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol. 2012, 69:29-38.
144. Irons B.K., Minze M.G. Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated. Diabetes Metab. Syndr. Obes. Targets Ther. 2014, 7:15-24.
145. Rena G., Pearson E.R., Sakamoto K. Molecular mechanism of action of metformin: old or new insights?. Diabetologia 2013, 56:1898-1906.
146. Burcelin R. The antidiabetic gutsy role of metformin uncovered?. Gut 2014, 63:706-707.
147. Chen Y., Zhou K., Wang R., Liu Y., Kwak Y.D., Ma T., Thompson R.C., Zhao Y., Smith L., Gasparini L., Luo Z., Xu H., Liao F.F. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:3907-3912.
148. Kickstein E., Krauss S., Thornhill P., Rutschow D., Zeller R., Sharkey J., Williamson R., Fuchs M., Kohler A., Glossmann H., Schneider R., Sutherland C., Schweiger S. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:21830-21835.
149. Gupta A., Bisht B., Dey C.S. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology 2011, 60:910-920.
150. Li J., Deng J., Sheng W., Zuo Z. Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice. Pharmacol. Biochem. Behav. 2012, 101:564-574.
151. McNeilly A.D., Williamson R., Balfour D.J., Stewart C.A., Sutherland C. A high-fat-diet-induced cognitive deficit in rats that is not prevented by improving insulin sensitivity with metformin. Diabetologia 2012, 55:3061-3070.
152. Correia S., Carvalho C., Santos M.S., Proenca T., Nunes E., Duarte A.I., Monteiro P., Seica R., Oliveira C.R., Moreira P.I. Metformin protects the brain against the oxidative imbalance promoted by type 2 diabetes. Med. Chem. 2008, 4:358-364.
153. Pintana H., Apaijai N., Pratchayasakul W., Chattipakorn N., Chattipakorn S.C. Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats. Life Sci. 2012, 91:409-414.
154. Alzoubi K.H., Khabour O.F., Al-Azzam S.I., Tashtoush M.H., Mhaidat N.M. Metformin eased cognitive impairment induced by chronic l-methionine administration: potential role of oxidative stress. Curr. Neuropharmacol. 2014, 12:186-192.
155. Imfeld P., Bodmer M., Jick S.S., Meier C.R. Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study. J. Am. Geriatr. Soc. 2012, 60:916-921.
156. Moore E.M., Mander A.G., Ames D., Kotowicz M.A., Carne R.P., Brodaty H., Woodward M., Boundy K., Ellis K.A., Bush A.I., Faux N.G., Martins R., Szoeke C., Rowe C., Watters D.A., Investigators A. Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care 2013, 36:2981-2987.
157. Hemmingsen B., Schroll J.B., Lund S.S., Wetterslev J., Gluud C., Vaag A., Sonne D.P., Lundstrom L.H., Almdal T. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. The Cochrane database of systematic reviews 2013, 4:CD009008.
158. Baraka A., ElGhotny S. Study of the effect of inhibiting galanin in Alzheimer's disease induced in rats. Eur. J. Pharmacol. 2010, 641:123-127.
159. Abdallah D.M., Nassar N.N., Abd-El-Salam R.M. Glibenclamide ameliorates ischemia-reperfusion injury via modulating oxidative stress and inflammatory mediators in the rat hippocampus. Brain Res. 2011, 1385:257-262.
160. Alp H., Varol S., Celik M.M., Altas M., Evliyaoglu O., Tokgoz O., Tanriverdi M.H., Uzar E. Protective effects of beta glucan and gliclazide on brain tissue and sciatic nerve of diabetic rats induced by streptozosin. Exp. Diabetes Res. 2012, 2012:230342.
161. Yau H., Rivera K., Lomonaco R., Cusi K. The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Curr. Diabetes Rep. 2013, 13:329-341.
162. Combs C.K., Johnson D.E., Karlo J.C., Cannady S.B., Landreth G.E. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J. Neurosci. 2000, 20:558-567.
163. Yan Q., Zhang J., Liu H., Babu-Khan S., Vassar R., Biere A.L., Citron M., Landreth G. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 2003, 23:7504-7509.
164. Galea E., Feinstein D.L., Lacombe P. Pioglitazone does not increase cerebral glucose utilisation in a murine model of Alzheimer's disease and decreases it in wild-type mice. Diabetologia 2006, 49:2153-2161.
165. Nohl H., Hegner D. Do mitochondria produce oxygen radicals in vivo?. Eur. J. Biochem. 1978, 82:563-567.
166. Nicolakakis N., Aboulkassim T., Ongali B., Lecrux C., Fernandes P., Rosa-Neto P., Tong X.K., Hamel E. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J. Neurosci. 2008, 28:9287-9296.
167. Heneka M.T., Sastre M., Dumitrescu-Ozimek L., Hanke A., Dewachter I., Kuiperi C., O'Banion K., Klockgether T., Van Leuven F., Landreth G.E. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 2005, 128:1442-1453.
168. Maeshiba Y., Kiyota Y., Yamashita K., Yoshimura Y., Motohashi M., Tanayama S. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 1997, 47:29-35.
169. Searcy J.L., Phelps J.T., Pancani T., Kadish I., Popovic J., Anderson K.L., Beckett T.L., Murphy M.P., Chen K.C., Blalock E.M., Landfield P.W., Porter N.M., Thibault O. Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease. J. Alzheimers Dis. 2012, 30:943-961.
170. Mandrekar-Colucci S., Karlo J.C., Landreth G.E. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-gamma-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J. Neurosci. 2012, 32:10117-10128.
171. Gupta R., Gupta L.K. Improvement in long term and visuo-spatial memory following chronic pioglitazone in mouse model of Alzheimer's disease. Pharmacol. Biochem. Behav. 2012, 102:184-190.
172. Yin Q.Q., Pei J.J., Xu S., Luo D.Z., Dong S.Q., Sun M.H., You L., Sun Z.J., Liu X.P. Pioglitazone improves cognitive function via increasing insulin sensitivity and strengthening antioxidant defense system in fructose-drinking insulin resistance rats. PLoS One 2013, 8:e59313.
173. Hanyu H., Sato T., Kiuchi A., Sakurai H., Iwamoto T. Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J. Am. Geriatr. Soc. 2009, 57:177-179.
174. Sato T., Hanyu H., Hirao K., Kanetaka H., Sakurai H., Iwamoto T. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol. Aging 2011, 32:1626-1633.
175. Pedersen W.A., Flynn E.R. Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. Neurobiol. Dis. 2004, 17:500-506.
176. Pedersen W.A., McMillan P.J., Kulstad J.J., Leverenz J.B., Craft S., Haynatzki G.R. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp. Neurol. 2006, 199:265-273.
177. Escribano L., Simon A.M., Perez-Mediavilla A., Salazar-Colocho P., Del Rio J., Frechilla D. Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem. Biophys. Res. Commun. 2009, 379:406-410.
178. Escribano L., Simon A.M., Gimeno E., Cuadrado-Tejedor M., Lopez de Maturana R., Garcia-Osta A., Ricobaraza A., Perez-Mediavilla A., Del Rio J., Frechilla D. Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 2010, 35:1593-1604.
179. O'Reilly J.A., Lynch M. Rosiglitazone improves spatial memory and decreases insoluble Abeta(1-42) in APP/PS1 mice. J. Neuroimmune Pharmacol. 2012, 7:140-144.
180. Strum J.C., Shehee R., Virley D., Richardson J., Mattie M., Selley P., Ghosh S., Nock C., Saunders A., Roses A. Rosiglitazone induces mitochondrial biogenesis in mouse brain. J. Alzheimers Dis. 2007, 11:45-51.
181. Watson G.S., Cholerton B.A., Reger M.A., Baker L.D., Plymate S.R., Asthana S., Fishel M.A., Kulstad J.J., Green P.S., Cook D.G., Kahn S.E., Keeling M.L., Craft S. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry 2005, 13:950-958.
182. Risner M.E., Saunders A.M., Altman J.F., Ormandy G.C., Craft S., Foley I.M., Zvartau-Hind M.E., Hosford D.A., Roses A.D., G.Rosiglitazone in Alzheimer's Disease Study Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 2006, 6:246-254.
183. Gold M., Alderton C., Zvartau-Hind M., Egginton S., Saunders A.M., Irizarry M., Craft S., Landreth G., Linnamagi U., Sawchak S. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement. Geriatr. Cogn. Disord. 2010, 30:131-146.
184. Squire L.R. Mechanisms of memory. Science 1986, 232:1612-1619.
185. Craft S., Watson G.S. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004, 3:169-178.
186. Moreira P.I., Santos M.S., Sena C., Seica R., Oliveira C.R. Insulin protects against amyloid beta-peptide toxicity in brain mitochondria of diabetic rats. Neurobiol. Dis. 2005, 18:628-637.
187. Duarte A.I., Candeias E., Correia S.C., Santos R.X., Carvalho C., Cardoso S., Placido A., Santos M.S., Olivera C.R., Moreira P.I. Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration. Biochim. Biophys. Acta 1832, 2013:527-541.
188. Duarte A.I., Proenca T., Oliveira C.R., Santos M.S., Rego A.C. Insulin restores metabolic function in cultured cortical neurons subjected to oxidative stress. Diabetes 2006, 55:2863-2870.
189. Duarte A.I., Santos P., Oliveira C.R., Santos M.S., Rego A.C. Insulin neuroprotection against oxidative stress is mediated by Akt and GSK-3beta signaling pathways and changes in protein expression. Biochim. Biophys. Acta 2008, 1783:994-1002.
190. De Felice F.G., Vieira M.N., Bomfim T.R., Decker H., Velasco P.T., Lambert M.P., Viola K.L., Zhao W.Q., Ferreira S.T., Klein W.L. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:1971-1976.
191. Garcia-Fernandez M., Delgado G., Puche J.E., Gonzalez-Baron S., Castilla Cortazar I. Low doses of insulin-like growth factor I improve insulin resistance, lipid metabolism, and oxidative damage in aging rats. Endocrinology 2008, 149:2433-2442.
192. Puche J.E., Garcia-Fernandez M., Muntane J., Rioja J., Gonzalez-Baron S., Castilla Cortazar I. Low doses of insulin-like growth factor-I induce mitochondrial protection in aging rats. Endocrinology 2008, 149:2620-2627.
193. Crowe E., Sell C., Thomas J.D., Johannes G.J., Torres C. Activation of proteasome by insulin-like growth factor-I may enhance clearance of oxidized proteins in the brain. Mech. Ageing Dev. 2009, 130:793-800.
194. Keller J.N., Hanni K.B., Markesbery W.R. Impaired proteasome function in Alzheimer's disease. J. Neurochem. 2000, 75:436-439.
195. Noh K.M., Lee J.C., Ahn Y.H., Hong S.H., Koh J.Y. Insulin-induced oxidative neuronal injury in cortical culture: mediation by induced N-methyl-d-aspartate receptors. IUBMB Life 1999, 48:263-269.
196. Ryu B.R., Ko H.W., Jou I., Noh J.S., Gwag B.J. Phosphatidylinositol 3-kinase-mediated regulation of neuronal apoptosis and necrosis by insulin and IGF-I. J. Neurobiol. 1999, 39:536-546.
197. Duarte A.I., Santos M.S., Seica R., Oliveira C.R. Oxidative stress affects synaptosomal gamma-aminobutyric acid and glutamate transport in diabetic rats: the role of insulin. Diabetes 2004, 53:2110-2116.
198. Patockova J., Marhol P., Tumova E., Krsiak M., Rokyta R., Stipek S., Crkovska J., Andel M. Oxidative stress in the brain tissue of laboratory mice with acute post insulin hypoglycemia. Physiol. Res. 2003, 52:131-135.
199. Dhuria S.V., Hanson L.R., Frey W.H. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci. 2010, 99:1654-1673.
200. Born J., Lange T., Kern W., McGregor G.P., Bickel U., Fehm H.L. Sniffing neuropeptides: a transnasal approach to the human brain. Nat. Neurosci. 2002, 5:514-516.
201. Hallschmid M., Schultes B., Marshall L., Molle M., Kern W., Bredthauer J., Fehm H.L., Born J. Transcortical direct current potential shift reflects immediate signaling of systemic insulin to the human brain. Diabetes 2004, 53:2202-2208.
202. Lund A., Knop F.K., Vilsboll T. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Eur. J. Intern. Med. 2014, 25:40-414.
203. Sarkar S., Fekete C., Legradi G., Lechan R.M. Glucagon like peptide-1 (7-36) amide (GLP-1) nerve terminals densely innervate corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Brain Res. 2003, 985:163-168.
204. Holscher C. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J. Endocrinol. 2014, 221:T31-T41.
205. Juillerat-Jeanneret L. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?. J. Med. Chem. 2014, 57:2197-2212.
206. Deacon C.F., Nauck M.A., Toft-Nielsen M., Pridal L., Willms B., Holst J.J. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995, 44:1126-1131.
207. Drucker D.J. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003, 26:2929-2940.
208. Drucker D.J. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin. Investig. Drugs 2003, 12:87-100.
209. Holscher C. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. Recent Pat. CNS Drug Discov. 2010, 5:109-117.
210. Perry T., Lahiri D.K., Sambamurti K., Chen D., Mattson M.P., Egan J.M., Greig N.H. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res. 2003, 72:603-612.
211. Li Y., Duffy K.B., Ottinger M.A., Ray B., Bailey J.A., Holloway H.W., Tweedie D., Perry T., Mattson M.P., Kapogiannis D., Sambamurti K., Lahiri D.K., Greig N.H. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J. Alzheimers Dis. 2010, 19:1205-1219.
212. Chen S., Liu A.R., An F.M., Yao W.B., Gao X.D. Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4. Age 2012, 34:1211-1224.
213. Kimura R., Okouchi M., Fujioka H., Ichiyanagi A., Ryuge F., Mizuno T., Imaeda K., Okayama N., Kamiya Y., Asai K., Joh T. Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway. Neuroscience 2009, 162:1212-1219.
214. Liu J., Yin F., Zheng X., Jing J., Hu Y. Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway. Neurochem. Int. 2007, 51:361-369.
215. Cai H.Y., Holscher C., Yue X.H., Zhang S.X., Wang X.H., Qiao F., Yang W., Qi J.S. Lixisenatide rescues spatial memory and synaptic plasticity from amyloid beta protein-induced impairments in rats. Neuroscience 2014, 10.1016/l.neuroscience.2014.02.022.
216. McClean P.L., Parthsarathy V., Faivre E., Holscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 2011, 31:6587-6594.
217. McClean P.L., Holscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. Neuropharmacology 2014, 76:57-67. (Pt A).
218. Parthsarathy V., Holscher C. Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model. PLoS One 2013, 8:e58784.
219. Mathieu C., Degrande E. Vildagliptin: a new oral treatment for type 2 diabetes mellitus. Vasc. Health Risk Manag. 2008, 4:1349-1360.
220. D'Amico M., Di Filippo C., Marfella R., Abbatecola A.M., Ferraraccio F., Rossi F., Paolisso G. Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. Exp. Gerontol. 2010, 45:202-207.
221. Kosaraju J., Gali C.C., Khatwal R.B., Dubala A., Chinni S., Holsinger R.M., Madhunapantula V.S., Muthureddy Nataraj S.K., Basavan D. Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease. Neuropharmacology 2013, 72:291-300.
222. Kosaraju J., Murthy V., Khatwal R.B., Dubala A., Chinni S., Muthureddy Nataraj S.K., Basavan D. Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease. J. Pharm. Pharmacol. 2013, 65:1773-1784.
223. Aviles-Olmos I., Dickson J., Kefalopoulou Z., Djamshidian A., Ell P., Soderlund T., Whitton P., Wyse R., Isaacs T., Lees A., Limousin P., Foltynie T. Exenatide and the treatment of patients with Parkinson's disease. J. Clin. Invest. 2013, 123:2730-2736.
224. Aviles-Olmos I., Dickson J., Kefalopoulou Z., Djamshidian A., Kahan J., Fmedsci P.E., Whitton P., Wyse R., Isaacs T., Lees A., Limousin P., Foltynie T. Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson's Disease. J. Parkinsons Dis. 2014, 10.3233/JPD-140364.